Experimental CAR-T therapy shows promise in small leukemia trial

NCT ID NCT05350787

Completed Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new CAR-T cell therapy called ThisCART19A in 10 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The main goals were to check safety and find the right dose. Researchers tracked side effects and how well the treatment shrank cancer cells in the first three months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ThisCART19A (a type of CAR-T cell therapy)
What this could lead to: If successful, this could point toward a new treatment option for patients with hard-to-treat B-cell leukemia who have few alternatives.
What could go wrong: This is a very early Phase 1 trial with only 10 participants, so results may not apply broadly. CAR-T therapies carry risks of severe side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-ALL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia precursor B-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-ALL

Contacts and locations

Locations

The First Hospital of Zhejiang Medical Colleage Zhejiang University

Hangzhou, Zhejiang, 310003, China
The first affiliated hospital of medical college of zhejiang university

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.